refocus on what's ahead

I thought it might be time to refocus and look what's instore for POH shareholders in 2011.

We know from the following sources - announcements, newletters and BRW article, Sky business interview and Blueballs SI document.

1. Anti-Acne Drug
Acne market $2b per annum.
Trials completed 4th Qtr 2011
Commercial Arrangements 4th Qtr 2011

2. Anti-Psoriasis
125 million sufferes world wide
FDA approval
Phase 1 trial (fully paid for) 1st Half 2011
Pre-clinical TPM increases effectiveness 5 fold.
License Arrangements post phase 1 trial including
fully paid for trials, milestone and royalty payments.

3. Mastitis (MMA)
costs industry $54B per annum world wide
Product launch 2nd Half 2011

4. Metier Tribecca
April 2011 - products expand from 2 to 10 products.
Intially new products as professional range
Launch into leading retail stores Qtr 3 2011
All costs covered including marketting etc.

5. AOD/Cellulite Cream
Market $3B per annum
Focus group results from leading US cosmetic testing lab 2nd Qtr 2011
Launch Australia April 2011
Launch USA 2nd Half 2011

6. Oxypatch/oxycodene
commercial scale development of patch
details of arrangement undisclosed
Results of patch development Qtr 3 2011
Commencement of Phase 2/3 trials Q3 2011

7. Elixia
Completion of Pulse exclusivity April 2011
Roll out of high performance line (5 produts) 2nd Qtr 2011
Expansion into India and SE Asia 3rd Qtr 2011

8. Vitamin D
trials conducted, awaiting results

9. Phusion Labs
12-24 months development of OTC applications.

10. CSL actives
continued association and collaboration
undisclosed details

11. Novartis Vetinary
continued association and collaboration in developing insulin for domesetic pets
undisclosed details

12. Insulin
In house completion of phase 1. On hold.

13. Diclofenac
In house further development of gel system

14. Diclofenac as treatment for actinic keratosis
proof of concept 3rd Qtr 2011
commercial discussions 2nd Half 2011

15. Oxy Gel for localised pain.
proof of concept 2nd Qtr 2011

16. Hair Care
announce license agreement 2nd Qtr 2011

17. Lidocaine
In house further development

Plus
From November Newletter pipeline:

2 undisclosed dermal products, can be psoriasis and acne, however retinoic can be the acne drug, leaving 1 undisclosed dermal product to come.

Plus, there remains 2 undisclosed cosmetic products in R&D stage in collaboration with a commercial partner.


Hope I haven't missed anything.
Onward and upward POH.